Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
NCT00083928 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2013-01-24
Summary
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of CA 125 levels.
Conditions
Interventions
- DRUG
-
Å6 subcutaneous injection
Sponsors & Collaborators
-
Ångstrom Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-05-31
- Primary Completion
- 2006-02-28
- Completion
- 2006-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
NCT05538624 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02312245 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
NCT00660101 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00101257 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
NCT02033616 ·Status: UNKNOWN ·Phase: PHASE2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00753480 ·Status: SUSPENDED ·Phase: PHASE1
-
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00006235 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00499252 ·Status: COMPLETED ·Phase: PHASE2
-
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
NCT01521143 ·Status: TERMINATED ·Phase: PHASE2
-
Ovarian Cancer Vaccine for Patients in Remission
NCT01068509 ·Status: COMPLETED ·Phase: PHASE2
-
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00288275 ·Status: TERMINATED
-
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01312389 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
NCT00660842 ·Status: UNKNOWN ·Phase: PHASE3
-
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489 ·Status: COMPLETED
-
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
NCT01016054 ·Status: TERMINATED ·Phase: PHASE1
-
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00006812 ·Status: TERMINATED ·Phase: PHASE2
-
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00582205 ·Status: TERMINATED ·Phase: PHASE2
-
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00096993 ·Status: COMPLETED ·Phase: PHASE2
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00287859 ·Status: TERMINATED ·Phase: PHASE1
-
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
NCT00127920 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
NCT00006453 ·Status: COMPLETED ·Phase: PHASE3